Spots Global Cancer Trial Database for A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
Official Title: An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C.
Study ID: NCT00502671
Conditions
Interventions
Study Description
Brief Summary: This single arm study will evaluate the safety profile of Xeloda as monotherapy for adjuvant treatment of colon cancer. All patients will receive Xeloda 1250mg/m2 p.o. twice daily as intermittent treatment (3 week cycles consisting of 2 weeks of treatment followed by 1 week without treatment). The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Arkhangelsk, , Russian Federation
, Astrakhan, , Russian Federation
, Barnaul, , Russian Federation
, Belgorod, , Russian Federation
, Chelyabinsk, , Russian Federation
, Ekaterinburg, , Russian Federation
, Irkutsk, , Russian Federation
, Izhevsk, , Russian Federation
, Kaluga, , Russian Federation
, Kazan, , Russian Federation
, Kazan, , Russian Federation
, Kirov, , Russian Federation
, Kostroma, , Russian Federation
, Krasnodar, , Russian Federation
, Kursk, , Russian Federation
, Lipetsk, , Russian Federation
, Moscow, , Russian Federation
, Moscow, , Russian Federation
, Moscow, , Russian Federation
, Moscow, , Russian Federation
, Moscow, , Russian Federation
, Moscow, , Russian Federation
, Nizhny Novgorod, , Russian Federation
, Novgorod Veliky, , Russian Federation
, Obninsk, , Russian Federation
, Orenburg, , Russian Federation
, Perm, , Russian Federation
, Rostov-na-donu, , Russian Federation
, Ryazan, , Russian Federation
, Salekhard, , Russian Federation
, Samara, , Russian Federation
, Smolensk, , Russian Federation
, Soshi, , Russian Federation
, St Petersburg, , Russian Federation
, St Petersburg, , Russian Federation
, Stavropol, , Russian Federation
, Surgut, , Russian Federation
, Tollyatti, , Russian Federation
, Tomsk, , Russian Federation
, Tomsk, , Russian Federation
, Tumen, , Russian Federation
, Tver, , Russian Federation
, UFA, , Russian Federation
, UFA, , Russian Federation
, Volgograd, , Russian Federation
, Yuzhno-Sakhalinsk, , Russian Federation
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
